Home > Boards > US Listed > Biotechs > INSMED (INSM)

Wow that`s a lot of cash. More than

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
blueyedcatch Member Profile
 
Followed By 13
Posts 5,546
Boards Moderated 0
Alias Born 07/14/16
160x600 placeholder
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 8/7/2020 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 7:31:30 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 7:31:02 AM
Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire (US) - 8/6/2020 7:30:00 AM
Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020 PR Newswire (US) - 7/27/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 9:38:47 AM
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infect... PR Newswire (US) - 7/24/2020 7:39:00 AM
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infect... PR Newswire (US) - 7/24/2020 7:36:00 AM
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patient... PR Newswire (US) - 7/7/2020 8:00:00 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 7/6/2020 8:00:00 AM
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at AT... PR Newswire (US) - 6/24/2020 4:01:00 PM
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCF... PR Newswire (US) - 6/8/2020 8:00:00 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 6/5/2020 8:00:00 AM
Insmed to Present at Two June Conferences PR Newswire (US) - 5/26/2020 8:00:00 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 5/21/2020 4:10:30 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 5/21/2020 4:08:11 PM
Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session PR Newswire (US) - 5/20/2020 9:29:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2020 4:02:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 10:59:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 8:32:02 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 5/7/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/5/2020 5:30:59 PM
Insmed Announces Pricing of Public Offering of Common Stock PR Newswire (US) - 5/5/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/4/2020 4:13:29 PM
Insmed Announces Proposed Public Offering of Common Stock PR Newswire (US) - 5/4/2020 4:01:00 PM
blueyedcatch   Monday, 09/11/17 10:57:21 PM
Re: fireopal post# 6460
Post # of 6484 
Wow that`s a lot of cash. More than enough extra to get Iplex going again. 377 million plus cash on hand,which is probably around 60 mln. They said 75 on the call,but that was for the end of June,so they`ve probably spent some of that 75 mln since,and that`s where I get the 60 mln. So a grand total of 430 mln minimum,and certainly a company in a position to start the new year off with super strength. Will Lewis has stated several times that he plans to turn Insmed into a stand alone big pharma,with multiple App`s for Arikace,and we`re hoping Iplex reborn,or another acquisition of a late stage drug,who knows. Point is the companies situated perfectly to achieve what Lewis declared he would do.Is it a ploy to sell Insm for the highest price possible?or is he really gonna do it?

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist